期刊文献+

维持性血液透析患者血浆同型半胱氨酸和血清脑钠肽检测的临床意义 被引量:6

The clinical significance of plasma HCY and serum BNP detection in maintenance hemodialysis patients
在线阅读 免费下载
分享 导出
摘要 目的:探讨维持性血液透析(maintenance hemodialysis,MHD)患者血浆同型半胱氨酸(homocysteine,Hcy)和血清脑钠肽(brain natriuretic peptide,BNP)水平与心血管疾病(cardiovascular disease,CVD)之间的关系。方法将95例 MHD患者分为心血管疾病组(CVD组)55例和无心血管疾病组(NCVD组)40例;另选30名健康对照者(健康对照组),检测各组血浆 Hcy、血清BNP、血肌酐(SCr)、血糖(glucose,GLU)、血白蛋白(albumin,Alb)、血脂并进行比较。结果 MHD患者血浆 Hcy [(26.89±10.12)μmol/L]明显高于健康对照组[(8.05±2.53)μmol/L](P〈0.01);血清 BNP [(1275.02±1123.94)pg/ml]显著高于对照组[(57.82±34.61)pg/ml](P〈0.01);其中 CVD 组血浆 Hcy[(31.73±10.18)μmol/L]高于 NCVD 组[(20.24±5.01)μmol/L](P〈0.01);血清 BNP [(1957.49±1001.83)pg/ml]高于 NCVD组[(336.61±308.22)pg/ml](P〈0.01)。以健康对照组血浆 Hcy 均数+2倍标准差(x+2s)(13.11μmol/L)为95%可信度上限,超过此值确定为高同型半胱氨酸血症(Hyperhomocysteinemia,HHcy)。95例 MHD患者 HHcy发生率为87.37%(83/95);其中CVD组 HHcy占94.55%(52/55),NCVD 组占77.50%(31/40),均明显高于正常对照组6.67%(2/30)(均 P〈0.01)。CVD 组和 NCVD 组 SCr、GLU、Alb 及血脂比较,差异无统计学意义(P〉0.05)。CVD组血浆 Hcy与 SCr、Alb呈正相关(r=0.380、0.354,P〈0.01),NCVD组血浆 HcyA与BNP、SCr、Alb呈正相关(r=0.341、0.337、0.389,P〈0.05),血清 BNP 与 Hcy、SCr 呈正相关(r=0.341、0.389,P〈0.05);血浆 Hcy、血清BNP与其余各血生化指标间无相关性(P〉0.05)。结论血浆 Hcy、血清BNP水平可作为 MHD患者CVD危险因素的预测指标。 Objective To study the relationship between plasma homocysteine (Hcy)and ser-um brain natriuretic petide (BNP)and the cardiovascular disease (CVD)in maintenance hemodialysis (MHD)patients.Methods Ninety-five patients with MHD were selected (MHD group)and divided into CVD group (including 55 cases)and NCVD group (including 40 cases)according to the incidence of CVD.Thirty healthy volunteers served as control group.Plasma HCY,serum BNP,serum creatinine (SCr),blood glucose (GLU),serum albumin (Alb)and blood lipid levels were measured and com-pared between MHD group and control group.Results The level of plasma HCY in MHD group was significantly higher than in control group [(26.89±10.12)vs.(8.05±2.53)μmol/L,P〈0.01]. The level of serum BNP in MHD group was significantly higher than in control group [(1 275.02 ±1 123.94)vs.(57.82±34.61)pg/ml,P〈0.01].In MHD group,the level of plasma HCY in CVD subgroup was significantly higher than in NCVD subgroup [(31.73±10.18)vs.(20.24±5.01)μmol/L,P〈0.01].The plasma Hcy in the control group x±2s (13.11μmol/L)was standardized as 95% confidence limit,and that exceeding this value was determined as HHcy.The incidence of HHcy in MHD group was 87.37% (83/95),and that in CVD subgroup and NCVD subgroup was 94.55%(52/55)and 77.50% (31/40)respectively,both were significantly higher than in control group [6.67% (2/30),P〈0.01].There was no significant difference in SCr,GLU,Alb and blood lipid be-tween CVD subgroup and NCVD subgroup (P〉0.05).In MHD group,the level of plasma Hcy in CVD subgroup was positively correlated with SCr and Alb (r=0.380 and 0.354,P〈0.01).The level of plasma Hcy in NCVD subgroup was positively correlated with SCr,Alb and BNP (r=0.341,0.337 and 0.389,P〈0.05).The level of BNP was positively correlated with plasma Hcy and SCr (r=0.341 and 0.389,P〈0.05).There was no correlation between plasma Hcy,BNP and the r
作者 蔡威巍 徐树人 于颖吉 朱纯 纪培颖 CAI Wei-wei, XU Shu-ren, YU Ying-ji, ZHU Chun, JI Pei-ying( Department of Nephrology , Shanghai Second People's Hospital, Shanghai 200011, China)
出处 《临床肾脏病杂志》 2014年第10期603-607,共5页 Journal Of Clinical Nephrology
基金 上海市黄浦区卫生和计划生育委员会优秀青年人才培养计划资助
关键词 血液透析 同型半胱氨酸 脑钠肽 心血管疾病 Hemodialysis Homocysteine Brain natriuretic peptide Cardiovascular disease
  • 相关文献

参考文献19

  • 1Pinto FC, Capone-Neto A, Prist R, et al. Volume replacement with lactated Ringer's or 3% hypertonic saline solution during combined experimental hemorrhagic shock and traumatic brain injury. J Trauma, 2006,60 : 758-764. 被引量:1
  • 2夏志银,马玉华,李大伟,郭昊,董海英,秦玉萍,于洋,支剑笙.维持性血液透析患者血浆sTWEAK蛋白表达[J].临床肾脏病杂志,2013(10):453-456. 被引量:1
  • 3Alessandra F, Pema DI. Possible mechanisms of homocysteine toxicity. Kid Int,2003,63(suppl 84):137-140. 被引量:1
  • 4Suliman ME, Stenvinkel P, Barany P, et al. Hyper homocys- teinemia, malnutrition, and inflammation in ESRD patients. Se- min Nephrol,2006,26:14-19. 被引量:1
  • 5Garibotto G,Sofia A, Valli A, et al. Causes of hyperhomocys- teinemia in patients with chronic kidney diseases. Semin Neph- rol,2006,26:1-7. 被引量:1
  • 6Suliman ME, Barany P, Kalantar-Eadeh K, et al. Homocystei- nein uremia-a puzzling and conflicting story. Nephrol Dial Transplant, 2005,20 : 16-21. 被引量:1
  • 7Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the eld- erly. Kidney Int,2003,63: 1121-1129. 被引量:1
  • 8Herrrnann W, Obeid R. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients. Clin Chem Lab Med, 2005,43 : 1039-1047. 被引量:1
  • 9Yi F, Li PL. Mechanisms of homocysteine-induced glomerular injuty and sclerosis. Am J Nephrology, 2008,28: 254-264. 被引量:1
  • 10Suliman ME, Stenvinkel P, Heimburger O, et al. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal fail- ure at start of dialysis therapy. Am J Kidney Dis, 2002,40:480- 488. 被引量:1

二级参考文献43

  • 1田军,张金元,胡大勇.肾功能损害对血浆同型半胱氨酸浓度的影响[J].中国血液净化,2005,4(10):542-544. 被引量:9
  • 2周文彦,倪兆慧,方炜,顾乐怡,王琴,牟姗,曹励欧,俞赞喆,钱家麒.慢性肾脏病非透析患者脑钠素与动脉粥样硬化及心功能的关系[J].中华肾脏病杂志,2007,23(3):162-166. 被引量:21
  • 3Susan viekery. American journal of kidney diseases, 2005,46; 610-662. 被引量:1
  • 4Richards M, Nicholls G, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol, 2006, 47: 52-60. 被引量:1
  • 5Vickery S, Price CP, John I, et al. B-type natriuretic peptide and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis, 2005, 46: 610-620. 被引量:1
  • 6Luchner A, Hengstenberg C, Lowel H, et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide and N-terminal pro-BNP. Hypertension, 2005, 46: 118-123. 被引量:1
  • 7DeFilippi CR, Fink JC, Nass CM, et al. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis, 2005, 46: 35-44. 被引量:1
  • 8SHAO Yong-hong, LAI Yu-qiong, LIN Ai-zhen, et al. Value of plasma brain natriuretic peptide detection in cardiac function assessment in hemodialysis patients. Di Yi Jun Yi Da Xue Xue Bao, 2005 , 25:892 -894. 被引量:1
  • 9Zeng C, Wei T, Jin L, et al. Value of B-type natriuretic peptide in diagnosing left ventricular dysfunction in dialysis-dependent patients. Intern Med J, 2006, 36: 552-557. 被引量:1
  • 10Topol EJ. Nesiritide-not verified. N Engl J Med, 2005, 353: 113-116. 被引量:1

共引文献10

同被引文献44

  • 1史晓敏,徐国宾,夏铁安.肾功能与N末端B型钠尿肽原的关系及其在慢性心力衰竭诊断中的应用[J].中华检验医学杂志,2006,29(12):1089-1092. 被引量:13
  • 2朱红俊,龚少愚,邹逊,魏慧渊,陆曙.心力衰竭病因对血浆BNP水平的影响[J].临床荟萃,2007,22(1):27-28. 被引量:23
  • 3戴兵,张黎明.尿素动力学模型及血液透析充分性.见:梅长林,主编.实用透析手册.第2版.北京:人民卫生出版社,2009.113-130. 被引量:7
  • 4周文彦,倪兆慧,顾乐怡,方炜,王琴,牟姗,曹励欧,俞赞喆,钱家麒.慢性肾脏病非透析患者脑钠素与肾功能及左室肥厚的关系[J].中华医学杂志,2007,87(46):3284-3287. 被引量:2
  • 5de Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest, 2004, 125(2):652-668. 被引量:1
  • 6Mikikallio AM, Mikikallio TH, Korpelainen JT, et al. Natriuretic peptides and mortality after stroke. Stroke, 2005, 36(5):1016-1020. 被引量:1
  • 7Leuchte HH, Baumgartner RA, Nounou ME. Brain natriuretic peptide is a prognostic parameter in chronic |ung disease. Am J Respir Crit Care Med, 2006, 173(7):744-750. 被引量:1
  • 8Stack, ACT, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure a- mong incident US dialysis patients[J]. Am J Kidney Dis, 2001, 38(5) : 992 t000. 被引量:1
  • 9Jarai R, Kaun C, Weiss TW, et al. Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin lalpha, tumour necrosis factor a] pha and transforming growth factor-beta[J]. J Cell Mol Med, 2009, 13(11 12): 4415 4421. 被引量:1
  • 10European Society of Cardiology. Guidelines for he diagnosis and treatment of chronic heart failure[J]. Eur J Heart, 2001 , 22(17): 1527 1560. 被引量:1

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈